Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human FGL1/HP-041-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications. |
Formulation: |
Supplied as a 0.22 Mu m filtered solution in 20mM Tris, 300mM NaCl, 10% Glycerol, pH 8.0 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Immunoreactivity: |
1.Measured by its binding ability in a functional ELISA. Immobilized recombinant Human FGL1 at 5 Mu g/mL (100 Mu L/well) can bind recombinant Human LAG3 with a linear range of 0.5-21.6 ng/mL.2.Measured by its binding ability in a functional ELISA. Im |
Gene Symbol: |
FGL1 |
Gene ID: |
2267 |
Uniprot ID: |
FGL1_HUMAN |
Immunogen Region: |
Met1-IIe312 |
Immunogen: |
Recombinant Human FGL1/HP-041 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Met1-IIe312) of human FGL1 (Accession #NP_004458.3) fused with a 6×His tag at the C-terminus. |
Function | Immune suppressive molecule that inhibits antigen-specific T-cell activation by acting as a major ligand of LAG3. Responsible for LAG3 T-cell inhibitory function. Binds LAG3 independently from MHC class II (MHC-II). Secreted by, and promotes growth of, hepatocytes. |
Protein Name | Fibrinogen-Like Protein 1Hp-041HepassocinHpsHepatocyte-Derived Fibrinogen-Related Protein 1Hfrep-1Liver Fibrinogen-Related Protein 1Lfire-1 |
Cellular Localisation | SecretedSecreted In The Blood Plasma |
Alternative Protein Names | Fibrinogen-Like Protein 1 proteinHp-041 proteinHepassocin proteinHps proteinHepatocyte-Derived Fibrinogen-Related Protein 1 proteinHfrep-1 proteinLiver Fibrinogen-Related Protein 1 proteinLfire-1 proteinFGL1 proteinHFREP1 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance